Cantor Fitzgerald Initiates Coverage On AbbVie with Overweight Rating, Announces Price Target of $200
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has initiated coverage on AbbVie (NYSE:ABBV) with an Overweight rating and a price target of $200.
May 17, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has initiated coverage on AbbVie with an Overweight rating and a price target of $200.
The initiation of coverage with an Overweight rating and a high price target of $200 by a reputable firm like Cantor Fitzgerald is likely to positively impact AbbVie's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100